These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37913732)

  • 1. Obeticholic acid-loaded exosomes attenuate liver fibrosis through dual targeting of the FXR signaling pathway and ECM remodeling.
    Azizsoltani A; Hatami B; Zali MR; Mahdavi V; Baghaei K; Alizadeh E
    Biomed Pharmacother; 2023 Dec; 168():115777. PubMed ID: 37913732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis.
    Zhou J; Huang N; Guo Y; Cui S; Ge C; He Q; Pan X; Wang G; Wang H; Hao H
    Acta Pharm Sin B; 2019 May; 9(3):526-536. PubMed ID: 31193776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3.
    Fan YY; Ding W; Zhang C; Fu L; Xu DX; Chen X
    Int Immunopharmacol; 2019 Dec; 77():105911. PubMed ID: 31671330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADSCs-derived exosomes ameliorate hepatic fibrosis by suppressing stellate cell activation and remodeling hepatocellular glutamine synthetase-mediated glutamine and ammonia homeostasis.
    Wu B; Feng J; Guo J; Wang J; Xiu G; Xu J; Ning K; Ling B; Fu Q; Xu J
    Stem Cell Res Ther; 2022 Oct; 13(1):494. PubMed ID: 36195966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.
    Zhang DG; Zhang C; Wang JX; Wang BW; Wang H; Zhang ZH; Chen YH; Lu Y; Tao L; Wang JQ; Chen X; Xu DX
    Toxicol Appl Pharmacol; 2017 Jan; 314():39-47. PubMed ID: 27865854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precise delivery of obeticholic acid
    Ji G; Ma L; Yao H; Ma S; Si X; Wang Y; Bao X; Ma L; Chen F; Ma C; Huang L; Fang X; Song W
    Acta Pharm Sin B; 2020 Nov; 10(11):2171-2182. PubMed ID: 33304784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
    Zhou J; Cui S; He Q; Guo Y; Pan X; Zhang P; Huang N; Ge C; Wang G; Gonzalez FJ; Wang H; Hao H
    Nat Commun; 2020 Jan; 11(1):240. PubMed ID: 31932588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice.
    Lin C; Yu B; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
    Front Pharmacol; 2022; 13():880508. PubMed ID: 35614939
    [No Abstract]   [Full Text] [Related]  

  • 11. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
    Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
    Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
    J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomes derived from human adipose mesenchymal stem cells ameliorate hepatic fibrosis by inhibiting PI3K/Akt/mTOR pathway and remodeling choline metabolism.
    Zhang Z; Shang J; Yang Q; Dai Z; Liang Y; Lai C; Feng T; Zhong D; Zou H; Sun L; Su Y; Yan S; Chen J; Yao Y; Shi Y; Huang X
    J Nanobiotechnology; 2023 Jan; 21(1):29. PubMed ID: 36698192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis.
    Comeglio P; Filippi S; Sarchielli E; Morelli A; Cellai I; Corcetto F; Corno C; Maneschi E; Pini A; Adorini L; Vannelli GB; Maggi M; Vignozzi L
    J Steroid Biochem Mol Biol; 2017 Apr; 168():26-37. PubMed ID: 28115235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomes from Human-Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells (hiPSC-MSCs) Protect Liver against Hepatic Ischemia/ Reperfusion Injury via Activating Sphingosine Kinase and Sphingosine-1-Phosphate Signaling Pathway.
    Du Y; Li D; Han C; Wu H; Xu L; Zhang M; Zhang J; Chen X
    Cell Physiol Biochem; 2017; 43(2):611-625. PubMed ID: 28934733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
    Namisaki T; Kaji K; Shimozato N; Kaya D; Ozutsumi T; Tsuji Y; Fujinaga Y; Kitagawa K; Furukawa M; Sato S; Sawada Y; Nishimura N; Takaya H; Okura Y; Seki K; Kawaratani H; Moriya K; Noguchi R; Asada K; Akahane T; Mitoro A; Yoshiji H
    Indian J Gastroenterol; 2022 Apr; 41(2):169-180. PubMed ID: 35279807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Wharton's jelly mesenchymal stem cells derived-exosomes enriched by miR-124 promote an anti-fibrotic response in an experimental model of liver fibrosis.
    Niknam B; Baghaei K; Mahmoud Hashemi S; Hatami B; Reza Zali M; Amani D
    Int Immunopharmacol; 2023 Jun; 119():110294. PubMed ID: 37167639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
    Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
    Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.
    Comeglio P; Filippi S; Sarchielli E; Morelli A; Cellai I; Corno C; Adorini L; Vannelli GB; Maggi M; Vignozzi L
    J Endocrinol Invest; 2019 Aug; 42(8):951-965. PubMed ID: 30674010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.